• Vemurafenib: Designing Better Melanoma Assays

  2026-08-16

  Vemurafenib and PLX4032 are valuable tools for modeling BRAF-driven melanoma biology. This guide shows how to connect early signaling, resistance phenotypes, and multi-omics evidence to make more informative cancer biology assays.

• Thymoquinone Protects Against Doxorubicin Cardiotoxicity

  2026-08-15

  A 2025 mouse study identifies thymoquinone as a potential countermeasure against doxorubicin-induced cardiac injury, linking functional protection with Nrf2/HO-1 activation, improved antioxidant status, and reduced ferroptosis-associated damage. Its findings provide a mechanistic foundation for preclinical cardiotoxicity research while leaving pathway causality, pharmacokinetics, and preservation of doxorubicin antitumor activity for future studies.

• Bufalin Targets STK33 in Triple-Negative Breast Cancer

  2026-08-14

  A 2025 Advanced Science study identifies serine/threonine kinase 33 (STK33) as a direct, degradation-sensitive target of the cardiotonic steroid Bufalin in triple-negative breast cancer. By combining chemical-proteomic target discovery, biophysical binding assays, genetic perturbation, animal models, and patient-derived organoids, the work connects Bufalin–STK33 engagement to disruption of an STK33–HSP90 stability mechanism and suppression of tumor growth.

• TMJ Inflammation, Microglia, and Synaptic Pruning

  2026-08-14

  This study identifies a mechanistic pathway linking temporomandibular joint inflammation to hippocampal microglial activation, neuronal C3 deposition, excessive synaptic pruning, and depression-like behaviors in mice. Its perturbation-based design highlights microglial Nr4a1 and neuronal C3 as experimentally testable nodes while clarifying the limits of translating these findings to other inflammatory signaling models.

• In Vitro Cancer Drug Response: Growth vs Death

  2026-08-13

  Hannah R. Schwartz’s dissertation distinguishes relative viability from fractional viability when measuring anticancer drug responses in vitro. The framework shows that growth inhibition and cell death are related but non-equivalent outcomes, supporting more informative assay design and interpretation.

• Deep Learning for iPSC-CM Cardiotoxicity Screening

  2026-08-13

  Grafton et al. developed a scalable high-content screening strategy that combines human iPSC-derived cardiomyocytes with deep-learning image analysis to identify drug-induced cardiotoxic phenotypes. Screening both annotated bioactive compounds and molecules with unknown targets showed that a single image-derived score can support early liability detection and chemical prioritization.

• Tetrahedral DNA Frameworks Improve Enzymatic DNA Synthesis

  2026-08-12

  The reference study engineers a tetrahedral DNA nanostructure interface that presents primers in a more ordered geometry for terminal-transferase-based oligonucleotide synthesis. Its results associate this architecture with improved enzyme accessibility, fewer deletion errors, and a practical DNA information-storage demonstration.

• Phytol: RXR Assays and the Architecture of Evidence

  2026-08-12

  Phytol supports a rigorous strategy for separating RXR activation from metabolic and GABAergic effects. This guide combines receptor pharmacology with lessons from polymer self-assembly to improve assay design, controls, and interpretation.

• Doxycycline Workflows for MMP2 Cancer Research

  2026-08-11

  Build reproducible Doxycycline experiments around antimicrobial activity, antiproliferative effects, and metalloproteinase inhibition. This workflow also shows how to use Doxycycline as a mechanistic control when evaluating MMP2-responsive peptide nanocarriers without confusing enzyme inhibition with targeted drug delivery.

• CPI-613 Workflows for Tumor Metabolism

  2026-08-11

  CPI-613 enables linked measurements of mitochondrial dysfunction, apoptosis, and tumor–immune metabolic signaling rather than relying on viability alone. This workflow-focused guide translates recent PDHA1 succinylation findings into practical assays for cholangiocarcinoma, acute myeloid leukemia research, and non-small cell lung carcinoma research.

• Busulfan Workflows for Senescence and Germ Cell Models

  2026-08-10

  Busulfan enables complementary experimental models: dose-controlled senescence induction in WI38 fibroblasts and chemically induced germ-cell depletion for ovarian lineage-tracing studies. This practical guide connects DNA crosslinking, MAPK readouts, dual-recombinase controls, formulation, and troubleshooting for more reproducible bench workflows.

• APEX2, TERT Expression, and Stem Cell DNA Repair

  2026-08-09

  This preprint identifies APEX2 as a previously unrecognized regulator of efficient TERT expression and telomerase activity in human embryonic stem cells. Its combination of knockdown, RNA-seq, and chromatin immunoprecipitation links repetitive DNA elements, particularly MIR sequences, to transcriptional control, while also highlighting important limitations for mechanistic and therapeutic interpretation.

• WM-8014 in Reproducible Cell Assays

  2026-08-08

  WM-8014 (SKU A8779) is a reversible, competitive KAT6A/B inhibitor for separating cell-cycle arrest and senescence from nonspecific cytotoxicity in cancer biology research. This scenario-based guide covers assay design, formulation limits, data interpretation, and practical supplier-selection criteria.

• (S)-(+)-Methoprene: Juvenile Hormone Pathways

  2026-08-07

  (S)-(+)-Methoprene is a juvenile hormone analog used to interrogate Met-dependent developmental signaling in arthropods. Its strongest research value is mechanistic: it links receptor activation and insect metamorphosis inhibition with experimental studies of hormone-regulated development, transcriptional control, and endocrine disruption.

• (S)-(+)-Methoprene: A Benchmark Juvenile Hormone Analog

  2026-08-07

  (S)-(+)-Methoprene is a potent and selective juvenile hormone analog used as a tool compound in studies of insect development and endocrine disruption. Its high-affinity activation of the Methoprene-tolerant receptor inhibits metamorphosis and maintains larval states, with broad utility in research on hormone-regulated processes. The compound’s low mammalian toxicity supports its role in comparative toxicology and receptor signaling investigations.

17052 records 1/1137 page Next 12345 下5页 Last page